Results 21 to 30 of about 32,177 (245)
Yap1-2 Isoform Is the Primary Mediator in TGF-β1 Induced EMT in Pancreatic Cancer
Frontiers in Oncology, 2021 Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive human malignancy and intrinsically resistant to conventional therapies. YAP1, as a key downstream effector of the Hippo pathway, plays an important role in tumorigenesis including PDAC ...
Chao Gao +14 more
doaj +1 more source
YAP1 Meets Tumor Suppression [PDF]
Molecular Cell, 2007 In this issue of Molecular Cell, Matallanas et al. (2007) demonstrate that RASSF1A-induced apoptosis impinges on the transcriptional coactivator YAP1, whose nuclear translocation and binding to p73 result in proper execution of the cell death pathway. Indeed, RASSF1A silencing in tumors inhibits YAP1-p73-dependent apoptosis.
Strano, Sabrina, Blandino, Giovanni
openaire +2 more sources
The TGFβ→TAK1→LATS→YAP1 Pathway Regulates the Spatiotemporal Dynamics of YAP1
Molecules and Cells, 2023 The Hippo kinase cascade functions as a central hub that relays input from the "outside world" of the cell and translates it into specific cellular responses by regulating the activity of Yes-associated protein 1 (YAP1). How Hippo translates input from the extracellular signals into specific intracellular responses remains unclear.
Min-Kyu Kim +13 more
openaire +2 more sources
CircSETD2 inhibits YAP1 by interaction with HuR during breast cancer progression
Cancer Biology & Therapy, 2023 CircRNAs have been proven to play a pivotal role in cancer progression. The present study aims to explore the roles and related mechanisms of circSETD2 in breast cancer proliferation, migration and invasion. The expression of circSETD2 in BC was assessed
Lan Jing +4 more
doaj +1 more source
Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma [PDF]
Journal of Clinical Investigation, 2019 Poroma is a benign skin tumor exhibiting terminal sweat gland duct differentiation. The present study aimed to explore the potential role of gene fusions in the tumorigenesis of poromas. RNA sequencing and reverse transcription PCR identified highly recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poromas (92/104 lesions, 88.5%) and their rare malignant ...
Shigeki Sekine +13 more
openaire +2 more sources
YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers. [PDF]
PLoS Genetics, 2015 YAP1 is a major effector of the Hippo pathway and a well-established oncogene. Elevated YAP1 activity due to mutations in Hippo pathway components or YAP1 amplification is observed in several types of human cancers.
Claudia Stein +10 more
doaj +1 more source
Interhemispheric Pediatric Meningioma, YAP1 Fusion-Positive
Diagnostics, 2022 Meningiomas are uncommon in children and usually arise in the context of tumor-predisposing syndromes. Recently, YAP1-fusions have been identified for the first time as potential NF2-independent oncogenic drivers in the development of meningiomas in pediatric patients.
Silvia Esposito +13 more
openaire +3 more sources
YAP1 promotes multidrug resistance of small cell lung cancer by CD74‐related signaling pathways
Cancer Medicine, 2020 Background Our previous research found that YAP1 may have a role in multidrug resistance (MDR) in small cell lung cancer (SCLC). However, its underlying mechanism is unknown.
Yongchun Song +4 more
doaj +1 more source
Cells, 2020 Background: Tumor-associated macrophages (TAMs) constitute a major portion of the leukocyte infiltrate found in breast cancer (BC). BC cells may reprogram TAMs in a pro-angiogenic and immunosuppressive sense.
Sara Donzelli +8 more
doaj +1 more source
Post-translational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease [PDF]
, 2016 Previous studies showed that YAP1 is over-expressed in hepatocellular carcinoma (HCC). Here we observed higher expression of Yap1/Ctgf axis in dysplastic nodules and HCC chemically-induced in F344 rats, genetically susceptible to hepatocarcinogenesis ...
Avila, Matias A. +13 more
core +2 more sources